Patients Desiring Immediate Postpartum Sterilization Should Not Be Required to Wait 30 Days.
Postpartum sterilization is a safe and effective form of contraception. It can be performed immediately after birth without increasing the length of stay in the hospital for new mothers. Unfortunately, women enrolled in Medicaid cannot elect to have a postpartum sterilization procedure performed until they have completed a federally required 30-day waiting period. In contrast, people with private insurance are not subjected to the 30-day waiting period.
In a new article published in The Lancet Regional Health – Americas, “Discriminatory Regulations on Postpartum Sterilization for Medicaid Recipients Propagate Health Inequities,” leading experts in obstetric care and members of the Society for Maternal-Fetal Medicine’s (SMFM) Health Policy and Advocacy Committee, Melanie Maykin, MD; Rachel Pilliod, MD; and Erika Werner, MD call for changes to the Medicaid policy that eliminates the two-tiered system of access to this form of contraception. The authors also call for policymakers to engage with patients who have been adversely affected by forced sterilizations or who have been denied sterilization due to the Medicaid waiting period.
Medicaid is the single largest payer of maternity benefits in the United States, covering approximately half of all births and a greater proportion of births among Black, Latinx, American Indian, and Alaskan Native communities. These communities are disproportionately impacted by the waiting period and are already fighting inequities before, during, and after pregnancy. This federal policy adds to these barriers and restricts reproductive autonomy.
While the authors address that the Medicaid waiting period was implemented to protect new mothers from unfair sterilization practices, they also note, “Nearly half of individuals with unfulfilled sterilization requests became pregnant within one year. These pregnancies represent substantial emotional, physical, and financial costs to birthing individuals.”
This press release was provided by the Society for Maternal-Fetal Medicine.
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
SMFM Consult Series #60: Management of pregnancies resulting from IVF
This Consult discusses the management of pregnancies achieved with in vitro fertilization and provides recommendations based on the available evidence.
Read More
This Consult has been endorsed by the American College of Obstetricians and Gynecologists (ACOG) and replaces the Society for Maternal-Fetal Medicine's (SMFM) Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016.
Read More